Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al

Will Dixon; Alan Silman

doi:10.1186/ar2026

Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al

Research output: Contribution to journal › Article › peer-review

Abstract

A recent meta-analysis of randomized clinical trials reported by Bongartz and coworkers raised concerns about an increased rate of malignancy and serious infection in rheumatoid arthritis patients treated with anti-tumour necrosis factor monoclonal antibodies. This commentary discusses some of the methodological issues in their analysis and urges caution in interpreting the results. © 2006 BioMed Central Ltd.

Original language	English
Article number	111
Journal	Arthritis Research and Therapy
Volume	8
Issue number	5
DOIs	https://doi.org/10.1186/ar2026
Publication status	Published - Oct 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/ar2026

Cite this

@article{745a2ec0a5644545b0543f42ea10876f,

title = "Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al",

abstract = "A recent meta-analysis of randomized clinical trials reported by Bongartz and coworkers raised concerns about an increased rate of malignancy and serious infection in rheumatoid arthritis patients treated with anti-tumour necrosis factor monoclonal antibodies. This commentary discusses some of the methodological issues in their analysis and urges caution in interpreting the results. {\textcopyright} 2006 BioMed Central Ltd.",

author = "Will Dixon and Alan Silman",

year = "2006",

month = oct,

doi = "10.1186/ar2026",

language = "English",

volume = "8",

journal = "Arthritis Research and Therapy",

issn = "1478-6354",

publisher = "Springer Nature",

number = "5",

}

TY - JOUR

T1 - Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al

AU - Dixon, Will

AU - Silman, Alan

PY - 2006/10

Y1 - 2006/10

N2 - A recent meta-analysis of randomized clinical trials reported by Bongartz and coworkers raised concerns about an increased rate of malignancy and serious infection in rheumatoid arthritis patients treated with anti-tumour necrosis factor monoclonal antibodies. This commentary discusses some of the methodological issues in their analysis and urges caution in interpreting the results. © 2006 BioMed Central Ltd.

AB - A recent meta-analysis of randomized clinical trials reported by Bongartz and coworkers raised concerns about an increased rate of malignancy and serious infection in rheumatoid arthritis patients treated with anti-tumour necrosis factor monoclonal antibodies. This commentary discusses some of the methodological issues in their analysis and urges caution in interpreting the results. © 2006 BioMed Central Ltd.

U2 - 10.1186/ar2026

DO - 10.1186/ar2026

M3 - Article

C2 - 16911768

SN - 1478-6354

VL - 8

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

IS - 5

M1 - 111

ER -

Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this